Abstract
The imatinib-sensitive fusion gene FIP1L1::PDGFRA is the most frequent molecular abnormality identified in patients with eosinophilic myeloid neoplasms. Rapid recognition of this mutation is essential given the poor prognosis of PDGFRA-associated myeloid neoplasms prior to the availability of imatinib therapy. We report a case of a patient in whom delayed diagnosis resulted in cardiac transplantation for eosinophilic endomyocardial fibrosis. The delay in diagnosis was due, in part, to a false-negative result in fluorescence in situ hybridization (FISH) testing for FIP1L1::PDGFRA. To explore this further, we examined our cohort of patients presenting with confirmed or suspected eosinophilic myeloid neoplasms and found 8 additional patients with negative FISH results despite a positive reverse-transcriptase polymerase chain reaction test for FIP1L1::PDGFRA. More importantly, false-negative FISH results delayed the median time to imatinib treatment by 257 days. These data emphasize the importance of empiric imatinib therapy in patients with clinical features suggestive of PDGFRA-associated disease.
Journal Section:
Case Report
References
1.
Valent
P
, Klion
AD
, Roufosse
F
, Simon
D
, Metzgeroth
G
, Leiferman
KM
. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
. Allergy
. 2023
;78
(1
):47
–59
. (in press). 2.
Gotlib
J
, Cools
J
. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
. Leukemia
. 2008
;22
(11
):1999
–2010
.3.
Klion
AD
, Noel
P
, Akin
C
, Law
M
, Gilliland
DG
, Cools
J
. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
. Blood
. 2003
;101
(12
):4660
–6
.4.
Cools
J
, DeAngelo
DJ
, Gotlib
J
, Stover
EH
, Legare
RD
, Cortes
J
. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
. N Engl J Med
. 2003
;348
(13
):1201
–14
.5.
Constantine
GM
, Ware
J
, Brown
T
, Thumm
L
, Kamal
N
, Kumar
S
. Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease
. J Allergy Clin Immunol Pract
. 2020
;8
(6
):2089
–91
.6.
Khoury
P
, Desmond
R
, Pabon
A
, Holland-Thomas
N
, Ware
JM
, Arthur
DC
. Clinical features predict responsiveness to imatinib in platelet derived growth factor receptor alpha-negative hypereosinophilic syndrome
. Allergy
. 2016
;71
(6
):803
–10
.7.
Score
J
, Walz
C
, Jovanovic
JV
, Jones
AV
, Waghorn
K
, Hidalgo-Curtis
C
. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions
. Leukemia
. 2009
;23
(2
):332
–9
.8.
Rheinbay
E
, Meifang
Q
, Bouyssou
JM
, Oler
AJ
, Thumm
L
, Makiya
M
. Genomics of PDGFR-rearranged hypereosinophilic syndrome
. bioRxiv
. 2022
9.
Metzgeroth
G
, Walz
C
, Erben
P
, Popp
H
, Schmitt-Graeff
A
, Haferlach
C
. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
. Br J Haematol
. 2008
;143
(5
):707
–15
.10.
Ogbogu
PU
, Bochner
BS
, Butterfield
JH
, Gleich
GJ
, Huss-Marp
J
, Kahn
JE
. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy
. J Allergy Clin Immunol
. 2009
;124
(6
):1319
25.e3
.11.
Jain
N
, Cortes
J
, Quintás-Cardama
A
, Manshouri
T
, Luthra
R
, Garcia-Manero
G
. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status
. Leuk Res
. 2009
;33
(6
):837
–9
.12.
Baccarani
M
, Cilloni
D
, Rondoni
M
, Ottaviani
E
, Messa
F
, Merante
S
. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
. Haematologica
. 2007
;92
(9
):1173
–9
.13.
Fang
H
, Tang
G
, Loghavi
S
, Greipp
P
, Wang
W
, Verstovsek
S
. Systematic use of fluorescence in situ hybridization (FISH) and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms
. Histopathology
. 2020
;76
(7
):1042
–54
.14.
Jan
M
, Grinshpun
DE
, Villalba
JA
, Dal Cin
P
, Sykes
DB
, Iafrate
AJ
. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia
. Blood Adv
. 2020
;4
(3
):445
–8
.15.
Reiter
A
, Gotlib
J
. Myeloid neoplasms with eosinophilia
. Blood
. 2017
;129
(6
):704
–14
.16.
Olsson-Arvidsson
L
, Norberg
A
, Sjögren
H
, Johansson
B
. Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis
. Br J Haematol
. 2020
;188
(5
):e76
–9
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
